WELCOME TO THE 2ND MEASURING PATIENT ENGAGEMENT SUMMIT 2025!
DEVELOPED TO ASSIST INDUSTRY IN BUILDING A QUANTITATIVE FRAMEWORK TO DEMONSTRATE IMPACT OF PATIENT ENGAGEMENT ACTIVITIES!
Uniting 70 + experts from Pfizer, UCB, Novartis, Day One Pharmaceuticals, PFMD and more, the 2nd Measuring Patient Engagement Summit still stands as the only industry event dedicated to measuring the success of patient engagement throughout the drug development lifecycle. This event will act as the honeypot gathering for leading patient engagement experts to share their latest experiences of how they are successfully demonstrating the impact of their patient engagement initiatives to:
- Showcase how the patient’s voice shapes decision-making to enhance their experience, strengthen trust in your company, and drive the adoption of life-changing treatments.
- Highlight the value of patient-focused investments to C-suite and leadership, especially in today’s challenging funding and layoff environment, reinforcing how these efforts directly improve patient outcomes.
- Present clear, objective metrics to regulatory bodies to increase the chances of drug approval and ensuring that vital therapies reach the patients who need them most.
EXAMINE
the Patient Engagement Impact Measurement Framework, understanding its pivotal role in shaping patient-centered drug development and integrating patient insights into healthcare systems, with expert insights from UCB and Novartis.
COLLABORATE
in the "Creating a Take-Home Framework with Multiple Metrics to Measure Success" session, where you and your peers will design a set of actionable, quantitative metrics to implement immediately in your patient engagement strategies, guided by ISPEP, PFMD, and Alnylam Pharmaceuticals.
PARTICIPATE
in deep-dive workshops to gain practical tools for demonstrating the value of patient advocacy, building internal support, and aligning with FDA requirements for patient experience data in NDAs, balancing both regulatory and commercial needs, with Stemline Therapeutics, Mallinckrodt Pharmaceuticals, Omeros Corporation, and PFMD
NAVIGATE
the path to standardized metric reporting across the drug development lifecycle, from engaging patients early in trial design to showcasing the impact of patient insights in marketing and commercialization, case studies presented by Pfizer, Eisai, Spark Therapeutics and more
IDENTIFY
key metrics to effectively communicate the value of patient engagement to C-suite, regulators, and patients, and learn how to tailor your metrics to each audience for maximum impact, with expert insights from UCB, Day One Therapeutics and more.
EXAMINE
the evolution of the Patient Engagement Impact Measurement Framework, understanding its pivotal role in shaping patient-centered drug development and integrating patient insights into healthcare systems, with expert insights from UCB and Novartis.
COLLABORATE
in the "Creating a Take-Home Framework with Multiple Metrics to Measure Success" session, where you and your peers will design a set of actionable, quantitative metrics to implement immediately in your patient engagement strategies, guided by ISPEP, PFMD, and Alnylam Pharmaceuticals.
PARTICIPATE
in deep-dive workshops to gain practical tools for demonstrating the value of patient advocacy, building internal support, and aligning with FDA requirements for patient experience data in NDAs, balancing both regulatory and commercial needs, with Stemline Therapeutics, Mallinckrodt Pharmaceuticals, Omeros Corporation, and PFMD
NAVIGATE
the path to standardized metric reporting across the drug development lifecycle, from engaging patients early in trial design to showcasing the impact of patient insights in marketing and commercialization, case studies presented by Pfizer, Eisai, Spark Therapeutics and more
IDENTIFY
key metrics to effectively communicate the value of patient engagement to C-suite, regulators, and patients, and learn how to tailor your metrics to each audience for maximum impact, with expert insights from UCB, Day One Therapeutics and more.